| 3294- | SIL, | Silymarin: a review on paving the way towards promising pharmacological agent |
| - | Review, | Nor, | NA | - | Review, | Arthritis, | NA |
| 3293- | SIL, | Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer |
| - | Review, | Var, | NA |
| 3292- | SIL, | Fe, | Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 |
| 3291- | SIL, | Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases |
| - | Review, | Nor, | NA |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3289- | SIL, | Silymarin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | NA, | NA |
| 4203- | SIL, | Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders |
| - | Review, | NA, | NA |
| 4204- | SIL, | Silymarin administration after cerebral ischemia improves survival of obese mice by increasing cortical BDNF and IGF1 levels |
| - | NA, | Stroke, | NA |
| 4205- | SIL, | The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review |
| - | Review, | AD, | NA |
| 4206- | SIL, | Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response |
| - | in-vivo, | NA, | NA |
| 3333- | SIL, | Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice |
| - | in-vivo, | NA, | NA |
| 3317- | SIL, | Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders |
| - | Review, | NA, | NA |
| 3318- | SIL, | Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3319- | SIL, | Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3320- | SIL, | Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action |
| - | Review, | AD, | NA |
| 3321- | SIL, | Silymarin (Milk thistle) |
| - | Review, | AD, | NA |
| 3316- | SIL, | Chemo, | Silymarin Nanoparticles Counteract Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights into Mitochondrial Dysfunction and Nrf2/HO-1 Axis |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 3323- | SIL, | Anticancer therapeutic potential of silibinin: current trends, scope and relevance |
| - | Review, | Var, | NA |
| 3332- | SIL, | Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2 |
| - | in-vitro, | Lung, | A549 |
| 3331- | SIL, | The clinical anti-inflammatory effects and underlying mechanisms of silymarin |
| - | Review, | NA, | NA |
| 3330- | SIL, | Mechanistic Insights into the Pharmacological Significance of Silymarin |
| - | Review, | Var, | NA |
| 3329- | SIL, | Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis) |
| - | in-vivo, | Nor, | NA |
| 3328- | SIL, | Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB |
| - | in-vivo, | BPH, | NA |
| 3327- | SIL, | Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia |
| - | in-vitro, | Liver, | HepG2 |
| 3326- | SIL, | Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B |
| 3325- | SIL, | Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury |
| - | in-vivo, | Nor, | NA |
| 3324- | SIL, | Silymarin prevents NLRP3 inflammasome activation and protects against intracerebral hemorrhage |
| 3655- | SIL, | Protective effect of silymarin on oxidative stress in rat brain |
| - | in-vivo, | AD, | NA |
| 3654- | SIL, | Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain |
| - | in-vivo, | AD, | NA |
| 3653- | SIL, | Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress |
| - | in-vivo, | AD, | NA |
| 3652- | SIL, | Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus |
| - | in-vivo, | NA, | NA |
| 3651- | SIL, | Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease |
| - | Trial, | NA, | NA |
| 3650- | SIL, | Silibinin: a novel inhibitor of Aβ aggregation |
| - | in-vitro, | AD, | SH-SY5Y |
| 3649- | SIL, | Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis |
| 3648- | SIL, | Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years |
| - | Review, | NA, | NA |
| 3647- | SIL, | Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation |
| - | in-vivo, | NA, | NA |
| 3646- | SIL, | "Silymarin", a promising pharmacological agent for treatment of diseases |
| - | Review, | NA, | NA |
| 1316- | SIL, | Chemo, | Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity |
| - | Analysis, | Var, | NA |
| 1276- | SIL, | Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells |
| - | in-vitro, | BC, | NA | - | in-vitro, | Thyroid, | NA |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 2306- | SIL, | CUR, | RES, | EA, | Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4207- | SIL, | Silymarin sex-dependently improves cognitive functions and alters TNF-α, BDNF, and glutamate in the hippocampus of mice with mild traumatic brain injury |
| 109- | SIL, | Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma |
| - | vitro+vivo, | RCC, | 769-P | - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | RCC, | OS-RC-2 |
| 1140- | SIL, | Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth |
| - | in-vitro, | PC, | AsPC-1 | - | in-vivo, | PC, | NA | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 1127- | SIL, | Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1 |
| - | in-vitro, | Lung, | A549 |
| 964- | SIL, | Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 |
| 1001- | SIL, | Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism |
| - | in-vitro, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid